Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres (R) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres (R) Transarterial Chemoembolization in Liver Cancer (CTILC) Study

doi:10.3727/096504019X15662966719585

科研成果详情

题名	Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres (R) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres (R) Transarterial Chemoembolization in Liver Cancer (CTILC) Study
作者	Sun, Junhui 1; Zhou, Guanhui 1; Xie, Xiaoxi 2; Gu, Wenjiang 3; Huang, Jing 4; Zhu, Dedong 5; Hu, Wenhao6; Hou, Qinming 7; Shi, Changsheng8; Li, Tiefeng 9; Zhang, Xin 10; Ji, Wenbin 11; Ying, Shihong 10; Peng, Zhiyi 10; Zhou, Jian 12; Yu, Zhihai 13; Ji, Jiansong 14; Du, Haijun 15; Guo, Xiaohua 16; Fang, Jian 17; Han, Jun 18; Xu, Huanhai 19; Sun, Zhichao 20; Yu, Wenqiang 21; Shao, Guoliang 22; Wu, Xia 23; Hu, Hongjie 23; Li, Ling 6; Zheng, Jiaping 22; Luo, Jun 22; Chen, Yutang 22; Cao, Guohong 24; Hu, Tingyang
发表日期	2020
发表期刊	ONCOLOGY RESEARCH 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Drug-eluting beads transarterial chemoembolization (DEB-TACE) Hepatocellular carcinoma (HCC) Clinical efficacy Safety Prognostic factors Liver function
其他关键词	DEB-TACE ; CONVENTIONAL CHEMOEMBOLIZATION ; STATISTICS
摘要	The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9-375) days, the 6-month PFS rate was 89.4 +/- 2.1%, while the mean OS was 380 (95% CI: 370-389) days, and the 6-month OS rate was 94.4 +/- 1.7%. Multivariate logistic regression revealed that portal vein invasion (p= 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p= 0.040), previous cTACE treatment (p=0.030), as well as abnormal serum creatinine level (BCr) (p= 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p= 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p=0.011) and total serum bilirubin (TBIL) (p= 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alaninc aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1-3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.
资助项目	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [LZ18H180001]; National S&T Major Project of China [2018ZX10301201]; Key Research Development Program of Zhejiang province [2018C03018]; Key Science and Technology Program of Zhejiang province [WKJ-ZJ-1923]
出版者	COGNIZANT COMMUNICATION CORP
出版地	PUTNAM VALLEY
ISSN	0965-0407
EISSN	1555-3906
卷号	28 期号:1 页码:75-94
DOI	10.3727/096504019X15662966719585
页数	20
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000512993600009
收录类别	SCIE ; SCOPUS
URL	查看原文
PubMed ID	31558180
SCOPUSEID	2-s2.0-85079077351
通讯作者地址	[Sun, Junhui]Hepatobiliary and Pancreatic Interventional Treatment Center,Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,College of Medicine,Zhejiang University,79 Qingchun Road,Hangzhou,310003,China
Scopus学科分类	Oncology;Cancer Research
引用统计	被引频次：12[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20701
专题	附属第一医院_介入科其他_附属第三医院（瑞安市人民医院）其他_附属第五医院（丽水市中心医院）
通讯作者	Sun, Junhui
作者单位	1.Hepatobiliary and Pancreatic Interventional Treatment Center,Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,China; 2.Interventional Center,Xinchang People’s Hospital,Shaoxing,China; 3.Department of Intervention,Jiaxing Second Hospital,Jiaxing,China; 4.Department of Hepatobiliary Surgery,Ningbo Medical Center,Lihuili Eastern Hospital,Ningbo,China; 5.Department of Liver Oncology,Ningbo No. 2 Hospital,Ningbo,China; 6.Department of Intervention,First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 7.Department of Radiology,Xixi Hospital of Hangzhou,Hangzhou 6th People’s Hospital,Hangzhou,China; 8.Department of Intervention,Third Affiliated Hospital of Wenzhou Medical University,Ruian,China; 9.Department of Radiology,Beilun District People’s Hospital of Ningbo,Ningbo,China; 10.Department of Radiology,First Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou,China; 11.Department of Radiology,Taizhou Hospital of Zhejiang Province,Linhai,China; 12.Department of Radiology,Hangzhou Cancer Hospital,Hangzhou,China; 13.Department of Vascular and Interventional Radiology,Affiliated Hospital of Medical College,Ningbo University,Ningbo,China; 14.Department of Radiology,Lishui Central Hospital,Lishui Hospital of Zhejiang University,Fifth Affiliated Hospital of Wenzhou Medical University,Lishui,China; 15.Department of Intervention,Dong Yang People’s Hospital,Dongyang,China; 16.Department of Intervention,Jinhua Central Hospital,Jinhua,China; 17.Department of Hepatobiliary Surgery,Quzhou People’s Hospital,Quzhou,China; 18.Department of Intervention,Jiaxing First Hospital,Jiaxing,China; 19.Division of Digestive Endoscopy,YueQing City People’s Hospital,Yueqing,China; 20.Department of Radiology,First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou,China; 21.Department of Intervention,Zhejiang Provincial People’s Hospital,Hangzhou,China; 22.Department of Intervention,Zhejiang Cancer Hospital,Hangzhou,China; 23.Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University College of Medicine,Hangzhou,China; 24.Department of Radiology,Shulan (Hangzhou) Hospital,Zhejiang University International Hospital,Hangzhou,China
推荐引用方式 GB/T 7714	Sun, Junhui,Zhou, Guanhui,Xie, Xiaoxi,et al. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres (R) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres (R) Transarterial Chemoembolization in Liver Cancer (CTILC) Study[J]. ONCOLOGY RESEARCH,2020,28(1):75-94.
APA	Sun, Junhui., Zhou, Guanhui., Xie, Xiaoxi., Gu, Wenjiang., Huang, Jing., ... & Hu, Tingyang. (2020). Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres (R) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres (R) Transarterial Chemoembolization in Liver Cancer (CTILC) Study. ONCOLOGY RESEARCH, 28(1), 75-94.
MLA	Sun, Junhui,et al."Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres (R) in 275 Hepatocellular Carcinoma Patients: Results From the Chinese CalliSpheres (R) Transarterial Chemoembolization in Liver Cancer (CTILC) Study".ONCOLOGY RESEARCH 28.1(2020):75-94.